At a CAGR of 13.8% over the course of the projection period, the genotyping assay market is expected to grow from USD 19.4 billion in 2024 to USD 37.1 billion in 2029. Advances in technology and falling DNA sequencing costs are anticipated to propel this market's growth. Recently, the industry has grown at a slower rate due to the increased prevalence of hereditary illnesses. Additionally, the field of customized medicine and medication development has made genotyping a major component.
Scope of the Report
Years Considered for the Study
2022-2029
Base Year
2023
Forecast Period
2024-2029
Units Considered
Value (USD Billion)
Segments
By product and services, technology, application, enduser, and region.
Regions covered
North America, Europe, Asia Pacific, Latin America, the Middle East & Africa and GCC Countries
Opportunities in the market are anticipated to arise from the need for genome analysis in plants and animal livestock, an increasing emphasis on national sequencing programs aimed at establishing genetic connections with disease, and the expanding fields of applications for genotyping. On the other hand, market expansion may be somewhat hampered by the high cost of equipment.
"Reagents & Kits segment accounted for the highest CAGR"
By product & service, the market is primarily segmented into reagents and kits, instruments, GENOTYPING ASSAY services, and bioinformatics. The reagents & kits segment accounted for the largest share of the Genotyping assay in 2023. The availability of a broad variety of reagents, the rising demand for reagents due to the rising volume of GENOTYPING ASSAY tests conducted worldwide, and the comparatively lower initial outlay needed to implement reagents and kits for GENOTYPING Assay in pharmacies and diagnostic facilities are all responsible for this segment's size.
"The polymerase chain reaction (PCR) segment accounted for the market share in the genotyping assay market, by technology, during the forecast period"
By technology, the market is primarily segmented into polymerase chain reaction (PCR), microarrays, capillary electrophoresis, sequencing, matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF), and other technologies (in situ hybridization and allele-specific oligonucleotides). The PCR segment accounted for the largest share of the GENOTYPING ASSAY technology market in 2023. The main factors propelling the growth of the PCR market are the introduction of new technologies like reverse transcriptase PCR, nested PCR, hot-start PCR, allele-specific PCR, and multiplex PCR; technological developments in PCR instruments and reagents; and the growing use of PCR technologies in the domains of genetics, prenatal testing, forensics, and personalized medicine.
"Pharmacogenomics segment accounted for the highest share"
By application, the market is primarily segmented into pharmacogenomics, diagnostics & personalized medicine, agricultural biotechnology, animal genetics, and other applications. The pharmacogenomics segment accounted for the largest share of the GENOTYPING ASSAY applications market in 2023. The primary drivers of growth in this market are the growing need for pharmacogenomics to investigate adverse drug reactions (ADRs) in clinical trials and the requirement to lower the total cost of medication development for pharmaceutical companies. The growing need for customized medication, the rise in hereditary and life-threatening illnesses, and ongoing research into effective and alternative drug delivery strategies are all anticipated to fuel the growth of the pharmacogenomics genotyping test.
"Biopharmaceutical & pharmaceutical companies segment accounted for the highest share"
By end user, the market is primarily segmented into biopharmaceutical & pharmaceutical companies, diagnostic laboratories, academic & research institutes, and other end users. The biopharmaceutical & pharmaceutical companies segment accounted for the largest share of the GENOTYPING ASSAY end-user market in 2023. The growing need for pharmacogenomics in the medication development process, the introduction of new products, and FDA recommendations to incorporate pharmacogenomics studies and GENOTYPING ASSAY in the drug discovery process are all responsible for this segment's size. Furthermore, the expansion of this market sector within GENOTYPING ASSAY is further facilitated by a rise in partnerships and funding for pharmacogenomics research.
"Asia Pacific: The fastest-growing region in cancer biomarkers market"
The global cancer biomarkers market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa and GCC Countries. The Asia Pacific region is projected to register the highest CAGR during the forecast period, primarily due to the increasing financial support from public as well as private agencies, increasing number of NGS-based research projects, increasing awareness about precision medicine, and high incidence of chronic diseases.
Breakdown of supply-side primary interviews, by company type, designation, and region:
By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
By Designation: C-level (27%), Director-level (18%), and Others (55%)
By Region: North America (51%), Europe (21%), Asia- Pacific (18%), Latin America (6%), and Middle East & Africa(4%)
Lists of Companies Profiled in the Report:
Thermo Fisher Scientific Inc. (US),
Illumina, Inc. (US),
Danaher Corporation (US),
QIAGEN (Netherlands),
Eurofins Scientific (Luxembourg),
F. Hoffmann-La Roche Ltd. (Switzerland),
Bio-Rad Laboratories, Inc. (US),
Merck KGAA (Germany),
Agilent Technologies (US),
Revvity Inc. (US),
Standard Bio Tools (US),
PacBio (US),
GENEWIZ Inc. (US),
Luminex Corporation (Diasorin Company) (US),
Oxford Nanopore Technologies Plc (UK),
GenScript (US),
Takara Bio Inc. (Japan),
New England Biolabs (US),
Promega Corporation (US),
Tecan Trading AG (Switzerland),
Genotypic Technology Pvt. Ltd. (India),
BGI GROUP (China),
Novogene Co., Ltd. (China),
Paragon Genomics, Inc. (US),
NeoGenomics Laboratories (US).
Research Coverage
This research report categorizes the genotyping assay market by product & services, technology, application, end-user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the optometry equipment market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the genotyping assay market. Competitive analysis of upcoming startups in the optometry equipment market ecosystem is covered in this report.
Reasons to buy this report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall genotyping assay market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
Analysis of key drivers (Technological advancements and reduced prices of DNA sequencing, Growing importance and use of genotyping in drug discovery and development), restraints (High manufacturing, installation, and maintenance costs of genotyping instruments), opportunities (Increasing application areas in genomics and genotyping analysis for animal genetics and agricultural biotechnology), and challenges (lack of adequate data management in genomics research) influencing the growth of the genotyping assay market.
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the genotyping assay market
Market Development: Comprehensive information about lucrative markets - the report analyses the genotyping assay market across varied regions.
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the genotyping assay market
Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Danaher Corporation (US), Eurofins Scientific (Luxembourg), and QIAGEN (Netherlands). among others in genotyping assay market.
TABLE 131 ASIA PACIFIC: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 132 LATIN AMERICA: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
7.6 MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY
7.6.1 INCREASING APPLICATIONS IN CLINICAL DIAGNOSTICS AND PHARMACOGENOMICS TO AID MARKET GROWTH
TABLE 133 KEY MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT PRODUCTS
TABLE 134 GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY REGION, 2022-2029 (USD MILLION)
TABLE 135 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 136 EUROPE: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 137 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 138 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
7.7 OTHER TECHNOLOGIES
TABLE 139 OTHER GENOTYPING TECHNOLOGIES
TABLE 140 GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2022-2029 (USD MILLION)
TABLE 141 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 142 EUROPE: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 143 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 144 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
8 GENOTYPING ASSAY MARKET, BY APPLICATION
8.1 INTRODUCTION
TABLE 145 GENOTYPING ASSAY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
8.2 PHARMACOGENOMICS
8.2.1 GROWING DEMAND FOR STUDYING ADVERSE DRUG REACTIONS IN CLINICAL TRIALS TO DRIVE MARKET
TABLE 146 GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY REGION, 2022-2029 (USD MILLION)
TABLE 147 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 148 EUROPE: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 149 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 150 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2022-2029 (USD MILLION)
8.3 DIAGNOSTICS & PERSONALIZED MEDICINES
8.3.1 INCREASING FOCUS ON DEVELOPING DIAGNOSTICS TESTS THROUGH RAPID GENOTYPING TO AID MARKET GROWTH
TABLE 151 GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY REGION, 2022-2029 (USD MILLION)
TABLE 152 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 153 EUROPE: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 154 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 155 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY COUNTRY, 2022-2029 (USD MILLION)
8.4 ANIMAL GENETICS
8.4.1 NEED TO INCREASE LIVESTOCK POPULATION TO PROPEL MARKET GROWTH
TABLE 156 GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY REGION, 2022-2029 (USD MILLION)
TABLE 157 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 158 EUROPE: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 159 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 160 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY COUNTRY, 2022-2029 (USD MILLION)
8.5 AGRICULTURAL BIOTECHNOLOGY
8.5.1 INCREASING USE OF PLANT GENOTYPING IN RESEARCH LABORATORIES AND GREENHOUSES TO FUEL MARKET GROWTH
TABLE 161 GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY REGION, 2022-2029 (USD MILLION)
TABLE 162 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 163 EUROPE: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 164 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 165 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
8.6 OTHER APPLICATIONS
TABLE 166 GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
TABLE 167 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 168 EUROPE: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 169 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 170 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
9 GENOTYPING ASSAY MARKET, BY END USER
9.1 INTRODUCTION
TABLE 171 GENOTYPING ASSAY MARKET, BY END USER, 2022-2029 (USD MILLION)
9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
9.2.1 RISING DEMAND FOR PHARMACOGENOMICS IN DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET
TABLE 172 GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2022-2029 (USD MILLION)
TABLE 173 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2029(USD MILLION)
TABLE 174 EUROPE: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2029(USD MILLION)
TABLE 175 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 176 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
9.3 DIAGNOSTIC LABORATORIES
9.3.1 GROWING PREFERENCE FOR PERSONALIZED MEDICINES TO AUGMENT MARKET GROWTH
TABLE 177 GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
TABLE 178 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029(USD MILLION)
TABLE 179 EUROPE: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 180 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 181 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
9.4 ACADEMIC & RESEARCH INSTITUTES
9.4.1 INCREASING INDUSTRY-ACADEMIA COLLABORATIONS FOR DRUG DEVELOPMENT TO SUPPORT MARKET GROWTH
TABLE 182 GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022-2029 (USD MILLION)
TABLE 183 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 184 EUROPE: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 185 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 186 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
9.5 OTHER END USERS
TABLE 187 GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
TABLE 188 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 189 EUROPE: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 190 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 191 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
10 GENOTYPING ASSAY MARKET, BY REGION
10.1 INTRODUCTION
TABLE 192 GENOTYPING ASSAY MARKET, BY REGION, 2022-2029 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 40 NORTH AMERICA: GENOTYPING ASSAY MARKET SNAPSHOT
TABLE 193 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 194 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 195 NORTH AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 196 NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 197 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 198 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022-2029 (USD MILLION)
TABLE 199 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022-2029 (USD MILLION)
TABLE 200 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 201 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 202 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY END USER, 2022-2029 (USD MILLION)
10.2.1 US
10.2.1.1 US to dominate North American genotyping assay market during forecast period
FIGURE 59 STANDARD BIOTOOLS: COMPANY SNAPSHOT (2023)
TABLE 429 STANDARD BIOTOOLS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.2 OTHER PLAYERS
12.2.1 REVVITY
TABLE 430 REVVITY: COMPANY OVERVIEW
12.2.2 PACBIO
TABLE 431 PACBIO: COMPANY OVERVIEW
12.2.3 LUMINEX CORPORATION (A DIASORIN COMPANY)
TABLE 432 LUMINEX CORPORATION (A DIASORIN COMPANY): COMPANY OVERVIEW
12.2.4 OXFORD NANOPORE TECHNOLOGIES PLC
TABLE 433 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY OVERVIEW
12.2.5 GENEWIZ, INC.
TABLE 434 GENEWIZ, INC.: COMPANY OVERVIEW
12.2.6 TAKARA BIO INC.
TABLE 435 TAKARA BIO INC.: COMPANY OVERVIEW
12.2.7 BGI GROUP
TABLE 436 BGI GROUP: COMPANY OVERVIEW
12.2.8 PROMEGA CORPORATION
TABLE 437 PROMEGA CORPORATION: COMPANY OVERVIEW
12.2.9 NOVOGENE CO., LTD.
TABLE 438 NOVOGENE CO., LTD.: COMPANY OVERVIEW
12.2.10 GENSCRIPT
TABLE 439 GENSCRIPT: COMPANY OVERVIEW
12.2.11 NEW ENGLAND BIOLABS
TABLE 440 NEW ENGLAND BIOLABS: COMPANY OVERVIEW
12.2.12 PARAGON GENOMICS, INC.
TABLE 441 PARAGON GENOMICS, INC.: COMPANY OVERVIEW
12.2.13 NEOGENOMICS LABORATORIES
TABLE 442 NEOGENOMICS LABORATORIES: COMPANY OVERVIEW
12.2.14 TECAN TRADING AG
TABLE 443 TECAN TRADING AG: COMPANY OVERVIEW
12.2.15 GENOTYPIC TECHNOLOGY PVT. LTD.
TABLE 444 GENOTYPIC TECHNOLOGY PVT. LTD.: COMPANY OVERVIEW
*Details on Business overview, Products/Services/Solutions offered, Recent developments, MnM view, Key strengths, Strategic choices, and Weaknesses and Competitive threats might not be captured in case of unlisted companies.